<DOC>
	<DOCNO>NCT01940770</DOCNO>
	<brief_summary>To confirm safety efficacy Bydureon long-term use Japanese patient type 2 diabetes mellitus actual drug use .</brief_summary>
	<brief_title>Specific Clinical Experience Investigation Long-term Use Bydureon</brief_title>
	<detailed_description>To confirm safety efficacy Bydureon ( hereinafter refer Bydureon ) long-term use Japanese patient type 2 diabetes mellitus actual drug use . 1 . Primary Objective To confirm safety profile Japanese patient type 2 diabetes mellitus receive Bydureon daily practice . 2 . Secondary objective As secondary objective S-CEI , follow item investigate . - Frequencies AEs relate cardiovascular event , hypoglycaemia , digestive symptom , injection site reaction . - Development pancreatitis , renal impairment ( especially acute renal failure ) , hypersensitivity reaction , malignant tumour ( especially thyroid tumour pancreatic malignancy ) - Safety patient mild moderate renal impairment - Changes weight , blood pressure , pulse rate , fast blood sugar , fast insulin , HbA1c , blood lipid - Bydureon administration daily practice focus patient 's demographic clinical characteristic diabetes mellitus ( duration diabetes mellitus , treatment duration , complication , Bydureon administration , etc ) - Anti-exenatide antibody titer AE case ( hypersensitivity , loss control blood sugar )</detailed_description>
	<mesh_term>Exenatide</mesh_term>
	<criteria>The patient type 2 diabetes mellitus inadequately respond sulfonylurea , biuguanides , and/or thiazolidines ( monotherapy combination use ) addition diet exercise . No past history hypersensitivity component Bydureon . Not patient diabetic ketoacidosis , diabetic coma/ precoma , and/ type 1 diabetes mellitus . Bydureon administer patient emergency situation severe infection operation . Not patient severe renal impairment , include receive dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes Mellitus ( DM )</keyword>
	<keyword>Bydureon</keyword>
	<keyword>Exenatide</keyword>
</DOC>